Saxon Interests Inc. Has $254,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Saxon Interests Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,563 shares of the biopharmaceutical company’s stock after acquiring an additional 535 shares during the quarter. Saxon Interests Inc.’s holdings in Pfizer were worth $254,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. Bradley Foster & Sargent Inc. CT lifted its position in shares of Pfizer by 3.2% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company’s stock valued at $7,586,000 after purchasing an additional 8,375 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Pfizer by 0.6% during the second quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 5,246 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Pfizer by 1.4% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company’s stock worth $5,339,000 after buying an additional 2,572 shares during the period. Blair William & Co. IL grew its position in shares of Pfizer by 85.9% in the second quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company’s stock valued at $54,654,000 after purchasing an additional 902,376 shares in the last quarter. Finally, Sienna Gestion increased its position in shares of Pfizer by 0.8% during the second quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company’s stock valued at $6,189,000 after buying an additional 1,771 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Trading Down 0.0 %

Shares of NYSE:PFE opened at $26.49 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market cap of $150.09 billion, a P/E ratio of 35.86, a PEG ratio of 0.64 and a beta of 0.64. The stock’s fifty day moving average price is $26.11 and its 200-day moving average price is $28.01.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. Sell-side analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.